Skip to content
type1.science
ObservationalActive, not recruitingNCT05515939

Evaluating the InPen in pediatric type 1 diabetes

A completed-enrolment observational study of Medtronic's InPen connected insulin pen in adolescents and young adults with T1D. No results posted; primary completion is estimated November 2026.

Primary endpoints

  • Change in hemoglobin A1c (HbA1c)

Results so far

No results posted. Active, not recruiting; estimated n=34; started 9 September 2022; primary completion estimated 30 November 2026. Live registry ages are 13–21 (was written as 2–17); lead sponsor is Wayne State University (was written as Stanford). Last update 20 August 2026.

The full picture

This study asks how a connected pen behaves in real adolescent and young-adult MDI care (registry ages 13–21). Until results post, it does not change the InPen/MiniMed Go ranking.